Does the media refer more to STOK or ZURA?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Stoke Therapeutics and 4 mentions for Zura Bio. Stoke Therapeutics' average media sentiment score of 0.78 beat Zura Bio's score of 0.34 indicating that Stoke Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or ZURA?

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 4 mentions for Zura Bio. Aurinia Pharmaceuticals' average media sentiment score of 0.48 beat Zura Bio's score of 0.34 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZURA or ZBIO more profitable?

Zura Bio's return on equity of -61.47% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -61.47% -54.11% Zenas BioPharma N/A -99.99% -58.06%

Does the media refer more to ZURA or ZBIO?

In the previous week, Zenas BioPharma had 6 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Zenas BioPharma and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Zenas BioPharma's score of -0.34 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AGIO or ZURA?

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 4 mentions for Zura Bio. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Zura Bio's score of 0.34 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GENB or ZURA more profitable?

Generate Biomedicines' return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Zura Bio N/A -61.47% -54.11%

Does the media refer more to GENB or ZURA?

In the previous week, Generate Biomedicines had 8 more articles in the media than Zura Bio. MarketBeat recorded 12 mentions for Generate Biomedicines and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Generate Biomedicines' score of -0.01 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zura Bio (ZURA) Competitors

$5.64 +0.01 (+0.09%)

As of 02:14 PM Eastern

Compare

ZURA vs. STOK, AUPH, ZBIO, AGIO, and GENB

Should you buy Zura Bio stock or one of its competitors? Zura Bio's main competitors and comparable companies include Stoke Therapeutics (STOK), Aurinia Pharmaceuticals (AUPH), Zenas BioPharma (ZBIO), Agios Pharmaceuticals (AGIO), and Generate Biomedicines (GENB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zura Bio compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Stoke Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Zura Bio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	10.82	-$6.89M	-$3.34	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

In the previous week, Stoke Therapeutics had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Stoke Therapeutics and 4 mentions for Zura Bio. Stoke Therapeutics' average media sentiment score of 0.78 beat Zura Bio's score of 0.34 indicating that Stoke Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.1% of Zura Bio shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Zura Bio has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Zura Bio	N/A	-61.47%	-54.11%

Stoke Therapeutics currently has a consensus target price of $43.00, indicating a potential upside of 39.09%. Zura Bio has a consensus target price of $14.00, indicating a potential upside of 148.45%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Stoke Therapeutics and Zura Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Zura Bio (NASDAQ:ZURA) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, suggesting a potential upside of 14.98%. Zura Bio has a consensus price target of $14.00, suggesting a potential upside of 148.45%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Zura Bio's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
Zura Bio	N/A	-61.47%	-54.11%

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 4 mentions for Zura Bio. Aurinia Pharmaceuticals' average media sentiment score of 0.48 beat Zura Bio's score of 0.34 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$311.51M	6.56	$287.20M	$2.29	6.71
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Aurinia Pharmaceuticals has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Zura Bio on 10 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Zenas BioPharma?

Zura Bio (NASDAQ:ZURA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

Zura Bio has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -1.03, indicating that its share price is 203% less volatile than the broader market.

Zura Bio has higher earnings, but lower revenue than Zenas BioPharma. Zura Bio is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Zenas BioPharma	$10M	188.79	-$377.74M	-$8.47	N/A

In the previous week, Zenas BioPharma had 6 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Zenas BioPharma and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Zenas BioPharma's score of -0.34 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zura Bio's return on equity of -61.47% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-61.47%	-54.11%
Zenas BioPharma	N/A	-99.99%	-58.06%

Zura Bio presently has a consensus target price of $14.00, indicating a potential upside of 148.45%. Zenas BioPharma has a consensus target price of $45.71, indicating a potential upside of 52.87%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Zura Bio beats Zenas BioPharma on 10 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

61.1% of Zura Bio shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 24.79%. Zura Bio has a consensus target price of $14.00, suggesting a potential upside of 148.45%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zura Bio has lower revenue, but higher earnings than Agios Pharmaceuticals. Zura Bio is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	36.52	-$412.78M	-$7.01	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Agios Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

In the previous week, Agios Pharmaceuticals had 2 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for Agios Pharmaceuticals and 4 mentions for Zura Bio. Agios Pharmaceuticals' average media sentiment score of 0.90 beat Zura Bio's score of 0.34 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Zura Bio	N/A	-61.47%	-54.11%

Summary

Zura Bio beats Agios Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Zura Bio compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Zura Bio has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	61.88	-$203.15M	-$1.59	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

In the previous week, Generate Biomedicines had 8 more articles in the media than Zura Bio. MarketBeat recorded 12 mentions for Generate Biomedicines and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.34 beat Generate Biomedicines' score of -0.01 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines' return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Zura Bio	N/A	-61.47%	-54.11%

61.1% of Zura Bio shares are owned by institutional investors. 12.4% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Generate Biomedicines presently has a consensus target price of $25.40, suggesting a potential upside of 65.20%. Zura Bio has a consensus target price of $14.00, suggesting a potential upside of 148.45%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts plainly believe Zura Bio is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Zura Bio beats Generate Biomedicines on 9 of the 14 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$534.55M	$3.70B	$6.98B	$13.02B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-4.99	10.43	269.27	25.24
Price / Sales	N/A	1,288.46	597.12	100.97
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	4.08	17.49	13.06	6.33
Net Income	-$99.35M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-5.61%	1.33%	0.91%	0.94%
1 Month Performance	11.36%	1.20%	1.59%	0.90%
1 Year Performance	227.62%	55.62%	67.34%	20.38%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.6489 of 5 stars	$5.64 +0.1%	$14.00 +148.4%	+254.1%	$534.55M	N/A	N/A	3	Earnings Report Analyst Forecast
STOK Stoke Therapeutics	2.8966 of 5 stars	$32.96 +2.3%	$43.00 +30.5%	+85.2%	$2.08B	$184.42M	N/A	100
AUPH Aurinia Pharmaceuticals	3.6451 of 5 stars	$15.37 -0.5%	$17.67 +14.9%	+26.4%	$2.06B	$283.05M	15.15	300	Analyst Forecast
ZBIO Zenas BioPharma	3.2966 of 5 stars	$32.44 +1.4%	$44.29 +36.5%	+74.7%	$2.02B	$10M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
AGIO Agios Pharmaceuticals	2.5912 of 5 stars	$32.69 +0.3%	$41.25 +26.2%	-8.6%	$1.95B	$54.03M	N/A	390

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. STOK, AUPH, ZBIO, AGIO, and GENB

How does Zura Bio compare to Stoke Therapeutics?

Summary

How does Zura Bio compare to Aurinia Pharmaceuticals?

Summary

How does Zura Bio compare to Zenas BioPharma?

Summary

How does Zura Bio compare to Agios Pharmaceuticals?

Summary

How does Zura Bio compare to Generate Biomedicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. STOK, AUPH, ZBIO, AGIO, and GENB

How does Zura Bio compare to Stoke Therapeutics?

Which has more volatility and risk, STOK or ZURA?

Which has preferable valuation & earnings, STOK or ZURA?

Does the media refer more to STOK or ZURA?

Do insiders and institutionals believe in STOK or ZURA?

Is STOK or ZURA more profitable?

Do analysts rate STOK or ZURA?

Summary

How does Zura Bio compare to Aurinia Pharmaceuticals?

Do analysts prefer AUPH or ZURA?

Is AUPH or ZURA more profitable?

Do institutionals & insiders have more ownership in AUPH or ZURA?

Does the media favor AUPH or ZURA?

Which has preferable earnings & valuation, AUPH or ZURA?

Which has more volatility & risk, AUPH or ZURA?

Summary

How does Zura Bio compare to Zenas BioPharma?

Which has more volatility & risk, ZURA or ZBIO?

Which has better valuation and earnings, ZURA or ZBIO?

Does the media refer more to ZURA or ZBIO?

Is ZURA or ZBIO more profitable?

Do analysts rate ZURA or ZBIO?

Do insiders & institutionals believe in ZURA or ZBIO?

Summary

How does Zura Bio compare to Agios Pharmaceuticals?

Do insiders and institutionals hold more shares of AGIO or ZURA?

Do analysts recommend AGIO or ZURA?

Which has better valuation & earnings, AGIO or ZURA?

Which has more volatility & risk, AGIO or ZURA?

Does the media prefer AGIO or ZURA?

Is AGIO or ZURA more profitable?

Summary

How does Zura Bio compare to Generate Biomedicines?

Which has stronger earnings & valuation, GENB or ZURA?

Does the media refer more to GENB or ZURA?

Is GENB or ZURA more profitable?

Do insiders & institutionals hold more shares of GENB or ZURA?

Do analysts rate GENB or ZURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools